Head of the Humoral Immunology lab at the Institute Pasteur (Paris). His lab’s current goals include studying the molecular basis of antibody B-cell responses to viruses such as HIV-1, Hepatitis viruses and emerging viruses, and the mechanisms by which anti-viral antibodies participate in controlling infections in humans.
The results of the ANRS EP47 VISCONTI (Viro-Immunological Sustained COntrol after Treatment Interruption) study provided proof of concept that a state of sustainable HIV remission may be induced in at least some people with HIV: the post-treatment controllers (PTC). Unlike natural controllers, PTCs presented a symptomatic primary HIV-1 infection with high viral load and low… Continue reading Viral dynamics of rebound and control following early treatment of HIV/SIV (NIH)
Early ART initiation seems to favor post-treatment control of infection. However, only a minority of the individuals who are treated early is able to control viremia once the treatment is interrupted. Through retrospective analyses of data available in the ANRS CO6 PRIMO cohort and the Post-treatment controllers in the ANRS VISCONTI study, we have identified… Continue reading ANRS 175 RHIVIERA 01_Assessment of HIV remission upon ART interruption in early treated individuals from ANRS CO6 PRIMO cohort carrying the MHC genotype B35(53)Bw4TTC2
ART initiation during primary HIV infection limits the establishment, diversity and distribution of the viral reservoir while preserving key lymphoid organs of the deleterious effects of persistent viral replication and chronic immune activation, favoring the optimal maturation of immune responses. Early ART initiation may even facilitate long-term post-treatment control in some individuals. Therapeutic interventions during… Continue reading ANRS 176 RHIVIERA 02_Assessment of HIV remission upon ART interruption in individuals initiating ART in combination with two long lasting bNabs during primary infection
The VISCONTI study proposed that post-treatment control (PTC) of HIV infection might be favored by early antiretroviral treatment (ART) initiation. However, a formal demonstration has not been established and the underlying mechanisms leading to PTC remain elusive. The pVISCONTI program aims to assess, in standardized conditions, the impact of early versus late ART initiation on… Continue reading A Non-Human Primate Model For HIV Remission (pVISCONTI)
Molinos-Albert LM, Baquero E, Bouvin-Pley M, Lorin V, Charre C, Planchais C, Dimitrov JD, Monceaux V, Vos M, Hocqueloux L, Berger J-L, Seaman MS, Braibant M, Avettand-Fenoël V, Sáez-Cirión A, Mouquet H
Cell Host Microbe. 2023 Aug 9;31(8):1275-1287.e8
Huot N, Rascle P, Planchais C, Contreras V, Passaes C, Le Grand R, Beignon AS, Kornobis E, Legendre R, Varet H, Saez-Cirion A, Mouquet H, Jacquelin B, Müller-Trutwin M. Front Immunol. 2021 Jun 16;12:695148. doi: 10.3389/fimmu.2021.695148. PMID: 34220857
Molinos-Albert LM, Lorin V, Monceaux V, Orr S, Essat A, Dufloo J, Schwartz O, Rouzioux C, Meyer L, Hocqueloux L, Sáez-Cirión A, Mouquet H & ANRS VISCONTI Study Group
Nature Communications Vol 13 : 1944 (2022)
Passaes C, Desjardins D, Chapel A, Monceaux V, Lemaitre J, Mélard A, Perdomo-Celis F, Planchais C, Gourvès M, Dimant N, David A, Dereuddre-Bosquet N, Barrail-Tran A, Gouget H, Guillaume C, Relouzat F, Lambotte O, Guedj J, Müller-Trutwin M, Mouquet H, Rouzioux C, Avettand-Fenoël V, Le Grand R, Sáez-Cirión A.
Nature Communications. 2024, 15(1), Article number: 178
